全文获取类型
收费全文 | 524033篇 |
免费 | 34916篇 |
国内免费 | 647篇 |
专业分类
耳鼻咽喉 | 7114篇 |
儿科学 | 17115篇 |
妇产科学 | 13671篇 |
基础医学 | 86267篇 |
口腔科学 | 14682篇 |
临床医学 | 45491篇 |
内科学 | 95789篇 |
皮肤病学 | 12290篇 |
神经病学 | 37547篇 |
特种医学 | 18779篇 |
外国民族医学 | 63篇 |
外科学 | 78338篇 |
综合类 | 8721篇 |
一般理论 | 121篇 |
预防医学 | 40009篇 |
眼科学 | 12358篇 |
药学 | 41367篇 |
中国医学 | 1011篇 |
肿瘤学 | 28863篇 |
出版年
2018年 | 5103篇 |
2015年 | 4671篇 |
2014年 | 6297篇 |
2013年 | 9957篇 |
2012年 | 13420篇 |
2011年 | 14841篇 |
2010年 | 8615篇 |
2009年 | 8039篇 |
2008年 | 14175篇 |
2007年 | 15296篇 |
2006年 | 15451篇 |
2005年 | 14915篇 |
2004年 | 14599篇 |
2003年 | 13911篇 |
2002年 | 13722篇 |
2001年 | 24272篇 |
2000年 | 25291篇 |
1999年 | 20746篇 |
1998年 | 5563篇 |
1997年 | 4820篇 |
1996年 | 5156篇 |
1995年 | 4729篇 |
1994年 | 4407篇 |
1993年 | 4233篇 |
1992年 | 15911篇 |
1991年 | 16479篇 |
1990年 | 16579篇 |
1989年 | 15936篇 |
1988年 | 14715篇 |
1987年 | 14575篇 |
1986年 | 13735篇 |
1985年 | 13130篇 |
1984年 | 9796篇 |
1983年 | 8402篇 |
1982年 | 4706篇 |
1981年 | 4369篇 |
1979年 | 9529篇 |
1978年 | 6984篇 |
1977年 | 5866篇 |
1976年 | 5708篇 |
1975年 | 6506篇 |
1974年 | 7721篇 |
1973年 | 7204篇 |
1972年 | 7026篇 |
1971年 | 6722篇 |
1970年 | 6221篇 |
1969年 | 5925篇 |
1968年 | 5627篇 |
1967年 | 5038篇 |
1966年 | 4480篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
We studied the effects of calcium on transparency in homogenates of cortical and nuclear cells from calf lenses. Calcium was mixed into samples of homogenate to final concentrations between 0 and 50 mM and the transparency of the calcium-treated homogenates was measured using laser transmittance. In the presence of 10 mM calcium, the transmittance of cortical homogenate decreased 50% while the nuclear homogenate lost less than 4% transmittance after 24 h at 37 degrees C. To better understand the contribution of cytoplasm and membranes to opacity, the nuclear and cortical homogenates were centrifuged to separate membranes from the cytoplasm. When 10 mM calcium was added to cortical homogenate which was then centrifuged, the transmittance of the membrane fraction decreased nearly 60%, while the fraction without membrane decreased only 10%. The strong effect of calcium on the membrane fraction was accompanied by an increase in specific gravity of membranes from 1.23 to 1.32. Ten- and 20 mM calcium had no effect on transparency of membranes or cytoplasm separated from nuclear homogenate, and 50 mM calcium produced only a slight opacity. The results indicate that an effect on membrane-protein interactions may be important in the loss of transparency produced by calcium in cells of lens cortex. 相似文献
992.
993.
Charles R. Ashby Yoshio Minabe Alon Toor Lyle D. Fishkin Martin I. Granoff Rex Y. Wang 《Drug development research》1994,31(3):228-236
This study examined the effect of acute and chronic administration of the selective 5-HT3 receptor antagonist BRL 46470A, an analog of granisetron, on the number of spontaneously active dopamine (DA) cells in the substantia nigra pars compacta (A9 or SNC) and the ventral tegmental area (A10 or VTA) in the rat. In the A10 area, the acute administration of BRL 46470A decreased the number of spontaneously active DA cells at a dose of 0.1 mg/kg (0.28 μmol/kg) ip, yet increased the number of spontaneously active DA cells at a dose of 0.3 mg/kg (0.84 μmol/kg). The chronic administration (21 days) of BRL 46470A appeared to produce a multiphasic dose-response curve. Thus, the chronic treatment with BRL 46470A increased the number of spontaneously active A10 DA cells at 0.03 (0.084 μmol) and 0.3 mg/kg, but decreased the number of spontaneously active A10 DA cells at a dose of 0.1 mg/kg. In contrast, BRL 46470A did not decrease the number of spontaneously active A9 DA cells after either acute or chronic administration (0.01-0.3 mg/kg). However, BRL 46470A did increase the number of spontaneously active A9 DA cells at acute and chronic doses similar to those that were effective in A10. The iv administration of (+)-apomorphine (APO) not only failed to reverse the decrease produced by chronic administration of BRL 46470A at 0.1 mg/kg, but further decreased the number of spontaneously active A10 DA cells. Similar to the results obtained with granisetron, the pretreatment of naive rats with either 0.01 or 0.1 mg/kg iv of BRL 46470A significantly potentiated (2-fold) the suppressant action of APO on the basal firing rate of A10, but not A9 DA cells. Overall, our results indicate that similar to granisetron, chronic BRL 46470A at 0.1 mg/kg selectively decreases the number of spontaneously active A10 DA cells, via a mechanism not related to depolarization inactivation. Presently, it is not clear what factors may contribute to the multiphasic dose-response curve of BRL 46470A. © 1994 Wiley-Liss, Inc. 相似文献
994.
For the treatment of intraabdominal infection, single-agent antimicrobial regimens such as β-lactams with good antianaerobic activity are frequent alternatives to combination regimens such as aminoglycosides or aztreonam plus an antianaerobic agent such as clindamycin or metronidazole. The major issues in selecting a regimen are relative efficacy, potential for adverse drug effects, and cost. Single agents are clearly equivalent to combinations in preventing infectious complications after penetrating abdominal trauma and in treating established intraabdominal infections of mild to moderate severity or in relatively low-risk patients. A few trials demonstrated their equivalency in patients at high risk of mortality, although experience is limited. Single-agent regimens may reduce the risks of adverse drug effects compared with combination regimens, but they are not always less expensive. 相似文献
995.
The effects of bilateral nucleus accumbens microinjections ofd-ala-met-enkephalinamide (DALA) were assessed in behavioral activation and lateral hypothalamic self-stimulation (LHSS) rate-frequency curve-shift paradigms in normal and accumbens 6-OHDA (4.0 µg) treated rats. Microinjections of DALA (2.5 µg/µl) in the behavioral activation paradigm had little effect on normal activity; however, DALA administered to 6-OHDA treated rats produced a significant overall increase in locomotion. The 6-OHDA DALA-induced locomotion effect peaked at 2 weeks after 6-OHDA treatment and then returned to baseline levels by week 5 posttreatment. Using LHSS, DALA tested over a range of doses (2.5, 5, 10, 20 µg/µl) displayed a weak biphasic reward effect only at the highest dose, which was characterized by an initial suppression followed by an elevation. DALA significantly depressed initial operant motor/performance in LHSS in a dose dependent fashion. Micro-injections of the normally ineffective low dose of DALA (2.5 µg/µl) following accumbens 6-OHDA treatment produced a significant LHSS reward decrease 2 weeks posttreatment, while LHSS motor/performance was relatively unaffected. Results are discussed in terms of opiate-dopamine and limbic-motor interactions. 相似文献
996.
Cocaethylene, a psychoactive metabolite resulting from combined ethanol/cocaine consumption, is of interest because its psychostimulant properties may partially underlie combined cocaine/ethanol use, and because it has the potential for use as a probe of drug reward mechanisms due to its enhanced selectivity at monoamine uptake sites compared to cocaine. To determine the relative systemic bioavailabilities of cocaine and cocaethylene, sequential plasma samples were obtained from awake rats following drug administration. Following intravenous administration of 3 µmol/kg (molar equivalent of 1 mg/kg cocaine-HCl), both drugs achieved similar time courses and areas under the plasma concentration versus time curve. In contrast, intraperitoneal administration of 44 µmol/kg (molar equivalent of 15 mg/kg cocaine HCl) showed peak plasma levels, and the area under the plasma concentration vs time curve for cocaine to be approximately twice that for cocaethylene. Comparison of dose corrected areas under the curve of the two routes of administration for each drug indicated that relative systemic bioavailability of cocaethylene following intraperitoneal administration is only 58% that of cocaine. In addition, the elimination of both cocaine and cocaethylene was found to be slower following intraperitoneal administration compared to the intravenous route. The implications of these results are discussed with respect to the relative potency of these two compounds, as inferred from behavioral, drug reward, and lethality studies. Also, the differences noted will need to be taken into account when making mechanistic interpretations from comparative drug reward studies. 相似文献
997.
The effects of adrenergic activation on aggressiveness and the aggression induced endocrine changes were tested in rats. α2 adrenoceptor blockers were used for enhancing activation of the adrenergic system, and changes in aggressiveness were tested in resident-intruder contests. Three experiments were conducted. In experiment 1, saline injected rats responded to the presence of an opponent by aggression and the increase in plasma ACTH and corticosterone. Intraperitoneal administration of 1 mg/kg CH-38083 (an α2 adrenoceptor antagonist) produced a several fold increase in clinch fighting and mutual upright scores, and also further enhanced the plasma ACTH and corticosterone response. In experiment 2, the effect of three doses (0.5, 1 and 2 mg/kg) of three different α2 adrenoceptor blockers CH-38083, idazoxan and yohimbine were tested. All the substances increased aggression at 0.5 and 1 mg/kg; at 2 mg/kg the effect of idazoxan and yohimbine disappeared, while with CH-38083 an additional increase was obtained. In yohimbine treated animals the enhancement of aggression was reduced already at 1 mg/kg. In experiment 3, indomethacin, a potent inhibitor of the catecholamine-induced ACTH release completely abolished the effects of the α2 adrenoceptor antagonist CH-38083: the intensity of agonistic interactions, as well as ACTH and corticosterone plasma concentrations, returned to control levels. The possible role of catecholamines and the stress hormones in the activation of aggression is discussed. 相似文献
998.
Zh. A. Mamyrbekova S. A. Soldatova V. I. Abelentsev T. I. Solov'eva V. N. Guryshev A. T. Soldatenkov 《Pharmaceutical Chemistry Journal》1994,28(3):198-202
Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 28, No. 3, pp. 48–51, March, 1994. 相似文献
999.
V. I. Nifontov N. P. Bel'skaya E. A. Shtokareva 《Pharmaceutical Chemistry Journal》1994,28(10):687-706
Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 28, No. 10, pp. 4–18, October 1994. 相似文献
1000.
M. M. Rasulov I. G. Kuznetsov A. G. Zabozlaev M. G. Voronkov 《Pharmaceutical Chemistry Journal》1994,28(7):441-445
Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 28, No. 7, pp. 3–6, July, 1994. 相似文献